Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

CLASSIC trial investigators

Research output: Contribution to journalArticlepeer-review

469 Citations (Scopus)

Fingerprint Dive into the research topics of 'Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences